News | June 14, 2024
Suven to acquire a majority stake in CDMO player ‘Sapala Organics’
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
EDQM has also issued a Certificate of Suitability for Allopurino
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Subscribe To Our Newsletter & Stay Updated
